Eculizumab (Soliris) for relapsing neuromyelitis optica spectrum disorders
NIHR HSRIC
Record ID 32016001034
English
Authors' recommendations:
Eculizumab is a drug to treat neuromyelitis optica spectrum disorders. Neuromyelitis optica is a rare condition that causes damage to nerves of the eye and spinal cord. The main symptoms include muscle weakness, impaired eyesight, nerve pain, spasms and problems with bladder and bowel function. Patients with neuromyelitis optica spectrum disorders have 'attacks' of new or worsening symptoms, known as 'relapses'. Eculizumab is delivered straight into the blood and could reduce the inflammation that causes these relapses.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/eculizumab-soliris-for-relapsing-neuromyelitis-optica-spectrum-disorders/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Antibodies, Monoclonal, Humanized
- Aquaporin 4
- Neuromyelitis Optica
- Recurrence
- Complement Inactivating Agents
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.